64 results about "Phagemid" patented technology

The invention relates to the improvement of endonuclease-based antimicrobials by blocking DNA repair of double-strand break(s) (DSB(s)) in prokaryotic cells. In this respect, the invention especially concerns a method involving blocking DNA repair after a nucleic acid has been submitted to DSB, in particular by a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated programmable double-strand endonuclease. The invention particularly relates to the use of an exogenous molecule that inhibits DNA repair, preferably a protein that binds to the ends of the double-stranded break to block DSB repair. The invention also relates to vectors, particularly phagemids and plasmids, comprising nucleic acids encoding nucleases and Gam proteins, and a pharmaceutical composition and a product containing these vectors and their application.

A method for selecting novel proteins such as growth hormone and antibody fragment variants having altered binding properties for their respective receptor molecules is provided. The method comprises fusing a gene encoding a protein of interest to the carboxy terminal domain of the gene III coat protein of the filamentous phage M13. The gene fusion is mutated to form a library of structurally related fusion proteins that are expressed in low quantity on the surface of a phagemid particle. Biological selection and screening are employed to identify novel ligands useful as drug candidates. Disclosed are preferred phagemid expression vectors and selected human growth hormone variants.

The present invention relates to a filamentous phage display method wherein the polypeptides of interest displayed on the phage particle are cotranslationally translocated across the cytoplasmic membrane of Gram-negative bacteria based on the signal recognition particle pathway. This method is particularly suitable for polypeptides, which are known to be difficult to display on phages, and for proteins of cDNA libraries and other combinatorial libraries, in particular when derived from very fast folding, stable protein scaffolds. The invention further relates to phage or phagemid vectors useful in the method comprising a gene construct coding for a fusion polypeptide comprising the polypeptide to be displayed on the phage particle and an N-terminal signal sequence promoting cotranslational translocation.

The present invention uses co-expression of protease inhibitors and protease sensitive therapeutic agents that results in their localized production within the target tissue and inactivation outside of the target tissue, thereby increasing therapeutic activity and reducing the systemic toxicity. Inactivation is also accomplished by engineering protease degradation sites within the therapeutic construct for proteases, preferably those that are under-expressed within the target tissue yet present in non-target tissues within the body, resulting in therapeutic activity within the target tissue and inactivation outside of the target tissue. Novel chimeric proteins secreted by bacteria are also described. The chimeric proteins include chimeric toxins targeted to neoplastic cells and cells of the immune system. Novel combination therapies of these protease inhibitor:chimeric toxin-expressing bacteria together with small-molecule and biologic agents are also described. Non-conjugative bacteria capable of delivering phage/phagemids expression cassettes for DNA and RNA-based therapeutics are also described.

The present invention uses co-expression of protease inhibitors and protease sensitive therapeutic agents including phage and phagemids delivering peptides, therapeutic antibodies, DNA and RNA-based therapeutics that results in treating inflammation of a variety of disorders including psoriasis, atopic dermatitis and inflammatory bowel disease. The invention also provides bacteria that inhibit the growth of intestinal parasites such as worms, and deliver siRNA or miRNA that have specific anti-parasitic effects that results in the reduction or elimination of the parasite.

The invention discloses a single-chain antibody of broad-spectrum anti-p21ras protein and a preparation method thereof. The gene segment of the single-chain antibody is constructed by connecting light and heavy chain variable region gene segments of monoclonal antibody hybridoma cell strains of the broad-spectrum anti-p21ras protein through flexible oligonucleotide linkers; the gene segment of the single-chain antibody is connected with a phagemid expression vector to construct recombinant phagemid; the recombinant phagemid is converted into amber inhibiting colon bacillus TG1 to perform fusion expression; the positive recombinant phagemid is identified by using indirect ELISA screening through phage library exhibition; the positive recombinant phagemid is converted into non-amber inhibiting colon bacillus BL21 (DE3) to perform soluble expression of the single-chain antibody; indirect enzyme-linked immunosorbent assay and immune cell and tissue chemical experiments prove that the single-chain antibody for the soluble expression has strong binding specificity with three p21ras proteins of H-ras, K-ras and N-ras and high affinity; and the single-chain antibody is used for constructing small molecular antibodies such as intracellular antigens and the like and used for diagnosis and research of ras gene related tumors.

The invention discloses a canine parvovirus single-domain antibody, and a preparation method and an application thereof. The canine parvovirus single-domain antibody has a nucleotide sequence as shown in SEQIDNO.1. The preparation method comprises the steps: immunizing an alpaca by a canine parvovirus inactivated vaccine, and taking peripheral blood to obtain alpaca anti-canine parvovirus serum; extracting RNA in the peripheral blood, and carrying out reverse transcription to generate cDNA; utilizing specific primers for amplification, and purifying a VHH fragment; connecting the VHH fragment with a phagemid vector, transforming TG1, and constructing a canine parvovirus single-domain antibody library; and enriching the antibody library by utilizing a canine parvovirus structural protein VP2, introducing into an expression bacterial strain E.coil HB2151, and utilizing IPTG to induce the canine parvovirus single-domain antibody VHH having the biological activity to be expressed. The prepared canine parvovirus single-domain antibody has the detection activity of 15 [mu]g/ml and the detection sensitivity of 250 ng/ml, and can be used as drugs applied for treating dogs with canine parvovirus disease.

The invention relates to a novel phagemid display system for packaging phagemid DNA into phagemid particles which completely avoids the use of helper phage. The system of the invention incorporates the use of bacterial packaging cell lines which have been transformed with helper plasmids containing all required phage proteins but not the packaging signals. The absence of packaging signals in these helper plasmids prevents their DNA from being packaged in the bacterial cell, which provides a number of significant advantages over the use of both standard and modified helper phage. Packaged phagemids expressing a protein or peptide of interest, in fusion with a phage coat protein such as g3p, are generated simply by transfecting phagemid into the packaging cell line.

This invention involves the phagemid in molecule biology field and medicine field. It is a preparation method of display peptide's phagemid. This method adopts the gene group plasmid of assistant phage fusion protein of coding foreign peptide and pIII coat protein, to co-transformation or successive-transformation F factor positive Isolates together with phagemid, so to obtain phagemid that display foreign peptide. The phagemid prepared by this method has high foreign peptide display level, and it is not necessarily prepare assistant phage so to simplified the process of preparation of assistant phage.

A general method and recombinant nucleic acid sequences, by means which the method selects a recombinant protein containing an FHA domain for binding a target molecule from a library proteins with a high-throughput method of creating protein variations within the FHA domain in non-conserved or non-structural sequences of the FHA scaffold, and the library may also be in the form of a phagemid or phage library wherein the ALP nucleic acid sequence is inserted into a vector capable of allowing the vector and expressed ALP protein from being virally packaged, and the recombinant nucleic acid sequences which are randomly mutated at varying non-conserved or non-structural FHA domain sequences.

The invention belongs to the technical field of antibodies and discloses a method for preparing PD-L1 (programmed death-ligand 1) nanoantibody by immunizing alpacas with a PD-L1 antigen. The method comprises: designing two synthetic primers, amplifying by PCR (polymerase chain reaction) to obtain sufficient target products for enzyme digestion, linking target fragments to a vector, converting, and carrying out screening and cloning; carrying out protein verifying and expressing; constructing an antibody library; displaying a VHH antibody library through an M13 bacteriophage display system which is composed of a pMECS phagemid vector, E. coli TG1 and an M13KO7 helper phage. In the phasmid vector pMECS, a sequence before a Pst I enzyme digestion site is a coding sequence for part of amino acids in first frame regions of pelB secretory signal peptides and antibodies; the pelB signal peptides can guide subsequent polypeptides secreted to periplasmic cavities; a sequence after a Not I enzyme digestion site is a coding sequence for HA and 6*His tags; the method is suitable for purification or detection of fusion proteins.

The present invention discloses one kind of lipopolysaccharide bindin and its monoclonal antibody, preparation process and use. Through extracting NH-LBP coding cDNA segment from human liver cell, preparing NH-LBP protein with insect sf21 cell, establishing humanized phage antibody base with pComb3H phagemid and screening with NH-LBP as antigen, anti-NH-LBP humanized monoclonal antibodies, Fab antibody and dsFv antibody are prepared. The Fab antibody and the dsFv antibody can combine specifically with the N end of complete human lipopolysaccharide bindin and inhibit the combination between LBP and LPS competively to lower the LPS sensitivity of body, lower LPS caused excessive inflammatory reaction, promote the degradation of LPS in body and prevent diffused blood coagulation inside capillary vessel and multiple organ failure.

The present invention relates to non-aggregating VH domains or libraries thereof. The V_H domains comprise at least one disulfide linkage-forming cysteine in at least one complementarity-determining region (CDR) and an acidic isoelectric point (pI). A method of increasing the power or efficiency of selection of non-aggregating V_H domains comprises panning a phagemid-based V_H domain phage-display library in combination with a step of selecting non-aggregating phage-V_H domains. Compositions of matter comprising the non-aggregating V_H domains, as well as methods of use are also provided.

The invention relates to an antibody gene for resisting pyrethriods pesticide scFv (Single Chain Fragment Variable), and particularly relates to construction of a pyrethriods pesticide antibody library, screening and sequence determination of a specific single-chain antibody gene and preparation of a specific phage display chain antibody. The antibody gene comprises nucleotide sequences of a coding heavy chain variable region (116 amino acids), a flexible chaining region (15 amino acids) and a light chain variable region (107 amino acids), shown as a SEQ ID No. 1 and a SEQ ID No.2 in a sequence table; and the antibody which is displayed on the surface of phage is prepared in a host cell by using phagemid. The antibody can be normally expressed and folded on the surface of the phage and can be used for well identifying pyrethriods antigens. Compared with a conventional antibody, the antibody has the advantages of high stability, convenient preparation and important potential application value.

The invention discloses a preparation method for circular single-stranded DNA integrated with aptamer and applications of the circular single-stranded DNA integrated with aptamer in DNA origami, and belongs to the field of DNA nanotechnologies and biological application. The preparation method mainly includes the following steps: (1.1) constructing circular double-stranded recombinant phagemid including an aptamer sequence; and (1.2) converting the constructed circular double-stranded recombinant phagemid into competent escherichia coli cells; and extracting the circular single-stranded DNA integrated with aptamer. Through the preparation method, a user defined skeleton chain sequence can be designed and produced, so as to add various function sequences at a user defined position. Problems of poor efficiency and stability of structural functionalization of traditional DNA origami can be broken through.

The present disclosure relates to vectors for cloning and expressing genetic material including but not limiting to antibody gene or parts thereof and methods of generating said vectors. Said vectors express the antibody genes in different formats such as Fab or scFv as a part of intertransfer system, intratransfer system or direct cloning and expression in individual display systems. In particular, phage display technology is used to clone and screen potential antibody genes in phagemid which is followed by the transfer of said genes to yeast vector for further screening and identification of lead molecules against antigens. The present vectors have numerous advantages including uniquely designed inserts/expression cassettes resulting in efficient and smooth transfer of clonal population from phage to yeast vectors resulting in efficient library preparation and identification of lead molecules.

Filamentous phage comprising a matrix of cpVIII proteins encapsulating a genome encoding first and second polypeptides of an antogenously assembling receptor, such as an antibody, and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a filamentous phage coat protein membrane anchor domain fused to at least one of the polypeptides.